Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 19/20 | 0.74 |
| ▸ | OXTR | P30559 | 13/20 | 0.74 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | TSPO | P30536 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570643 | 0.91 | AVPR1A (0.65) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18917221 | 0.90 | AVPR1A (0.63) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2129142 | 0.90 | AVPR1A (0.61) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2704576 | 0.90 | AVPR1A (0.61) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL5567012 | 0.90 | AVPR1A (0.63) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL9961437 | 0.89 | AVPR1A (0.72) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL18944536 | 0.89 | AVPR1A (0.80) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL30046134 | 0.88 | AVPR1A (0.75) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL26185549 | 0.88 | AVPR1A (0.75) | AVPR1AOXTRAVPR2CHRM2CHRM4 | |
| SCHEMBL2702943 | 0.88 | AVPR1A (0.59) | AVPR1AOXTRAVPR2CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | claimed |
| EP-1416941-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2023-10-19 | — | — | US | disclosed |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | SCRIPPS RESEARCH INST (US) | 2017-11-16 | — | — | US | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| WO-2014127350-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-08-21 | — | — | WO | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | AVPR1A 8/4885OXTR 1/4885AVPR2 15/4885 |
| US-20150376198-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885OXTR 6/4885AVPR2 1/4885 |
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | AVPR1A 7/4885OXTR 1/4885AVPR2 10/4885 |
| US-20170327512-A1 | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885OXTR 6/4885AVPR2 1/4885 |
| US-20230330103-A1 | NON-PEPTIDE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR1B, AVPR1A | AVPR1A 3/4885OXTR 1/4885AVPR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.